GlobeNewsWire
24 Feb 2026, 21:00 UTC · 35w ago
Verdict
Headline takes no side. We score DAWN +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Day One projects 2026 U.S. net product revenue for OJEMDA to be between $225 million and $250 million.
So whatThis provides concrete, high-growth guidance that significantly exceeds the 2025 full-year revenue of $155.4 million.
More positive than 99% of claims this week
Day One reported full year 2025 net product revenues of $155.4 million and Q4 revenues of $52.8 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
The company expanded its pipeline through the January 2026 acquisition of Mersana Therapeutics, adding Emi-Le for the treatment of adenoid cystic carcinoma.
More positive than 76% of claims this week
Enrollment for the FIREFLY-2 trial has been completed as of 2026.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported strong product revenues, reaffirmed its 2026 outlook, and expanded its pipeline through an acquisition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
+79.1%
Price agrees with the score
$21.53 vs $12.02 close before publication (Feb 24) · not market-adjusted
DAWN chart →
